{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05626114",
            "orgStudyIdInfo": {
                "id": "GR44251"
            },
            "organization": {
                "fullName": "Genentech, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration",
            "officialTitle": "A Phase IIa, Multicenter, Open-Label, Single-Arm Study To Optimize Subretinal Surgical Delivery And To Evaluate Safety And Activity Of Opregen In Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-optimize-subretinal-surgical-delivery-and-to-evaluate-safety-and-activity-of-opregen-in-participants-with-geographic-atrophy-secondary-to-age-related-macular-degeneration"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-04-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-04-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-11-15",
            "studyFirstSubmitQcDate": "2022-11-15",
            "studyFirstPostDateStruct": {
                "date": "2022-11-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Genentech, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated."
        },
        "conditionsModule": {
            "conditions": [
                "Geographic Atrophy"
            ],
            "keywords": [
                "Geographic Atrophy secondary to Age-related Macular Degeneration"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "OpRegen",
                    "type": "EXPERIMENTAL",
                    "description": "OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space",
                    "interventionNames": [
                        "Biological: OpRegen"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "OpRegen",
                    "description": "OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space",
                    "armGroupLabels": [
                        "OpRegen"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of Patients With Subretinal Surgical Delivery of OpRegen to Target Regions",
                    "timeFrame": "3 months post surgery"
                },
                {
                    "measure": "Incidence and Severity of Procedure-related Adverse Events at 3 Months Following Surgery",
                    "timeFrame": "3 months post surgery"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of Patients With Qualitative Improvement in Retinal Structure, as Determined by OCT Imaging Within 3 Months Following Surgery",
                    "timeFrame": "3 months post surgery"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Ability to undergo a vitreoretinal surgical procedure under monitored anesthesia care\n* Diagnosis of GA secondary to AMD\n* BCVA score \\>/= 35 letters and \\</= 60 letters in the study eye as assessed by ETDRS\n* Pseudophakic (study eye)\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* History of cognitive impairment or dementia\n* Any type of systemic disease or its treatment, in the opinion of the investigator, including any medical conditions that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk\n\nOcular Exclusion Criteria for Study Eye:\n\n* Any current or history of ocular disease other than GA that may confound assessment of the macula\n* History of retinal detachment\n* History of vitrectomy, glaucoma-filtering surgery, or corneal transplant\n* Uncontrolled glaucoma or advanced glaucoma\n* Any cataract surgery or intraocular surgery within 3 months prior to subretinal surgical delivery of OpRegen\n* History of other ocular or intraocular conditions that contraindicate the use of an investigational drug or may affect interpretation of the study results or may render the patient at high risk for treatment complications",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "50 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: GR44251 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S. Only)",
                    "email": "global-roche-genentech-trials@gene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Hoffmann-La Roche",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Retina-Vitreous Associates Medical Group",
                    "status": "RECRUITING",
                    "city": "Beverly Hills",
                    "state": "California",
                    "zip": "90211",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.07362,
                        "lon": -118.40036
                    }
                },
                {
                    "facility": "Retinal Consultants Medical Group",
                    "status": "RECRUITING",
                    "city": "Sacramento",
                    "state": "California",
                    "zip": "95825",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.58157,
                        "lon": -121.4944
                    }
                },
                {
                    "facility": "West Coast Retina",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94109-5520",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Cincinnati Eye Institute",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45242",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Mid Atlantic Retina",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19038",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008268",
                    "term": "Macular Degeneration"
                },
                {
                    "id": "D000057092",
                    "term": "Geographic Atrophy"
                },
                {
                    "id": "D000001284",
                    "term": "Atrophy"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012162",
                    "term": "Retinal Degeneration"
                },
                {
                    "id": "D000012164",
                    "term": "Retinal Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                },
                {
                    "id": "D000020763",
                    "term": "Pathological Conditions, Anatomical"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4589",
                    "name": "Atrophy",
                    "asFound": "Atrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11260",
                    "name": "Macular Degeneration",
                    "asFound": "Age-related Macular Degeneration",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28712",
                    "name": "Geographic Atrophy",
                    "asFound": "Geographic Atrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14997",
                    "name": "Retinal Degeneration",
                    "relevance": "LOW"
                },
                {
                    "id": "M14999",
                    "name": "Retinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22519",
                    "name": "Pathological Conditions, Anatomical",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                }
            ]
        }
    },
    "hasResults": false
}